AKBA Q2 2023 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-55.4% YoY

Gross Profit

$39M69.3% margin

Operating Income

-$9M-16.0% margin

Net Income

-$11M-19.8% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+40.9%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$254M

Total Liabilities

$281M

Stockholders' Equity

-$27M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$126M	-55.4%
Gross Profit	$39M	$108M	-63.7%
Operating Income	-$9M	$34M	-126.4%
Net Income	-$11M	$29M	-137.9%

Revenue Segments

Product

$42M75%

License Collaboration And Other Revenue

$14M25%